Alterations in serum kynurenine pathway metabolites in individuals with high neocortical amyloid-Î2 load: A pilot study

Recommended Citation Chatterjee, P., Goozee, K., Lim, C. K., James, I., Shen, K., Jacobs, K. R., Sohrabi, H. R., Shah, T., Asih, P. R., Dave, P., Manyan, C., Taddei, K., Lovejoy, D. B., Chung, R., Guillemin, G. J., & Martins, R. N. (2018). Alterations in serum kynurenine pathway metabolites in individuals with high neocortical amyloid-β load: A pilot study. DOI: https://doi.org/10.1038/s41598-018-25968-7

[1]  M. Garg,et al.  Elevated plasma ferritin in elderly individuals with high neocortical amyloid-β load , 2018, Molecular Psychiatry.

[2]  Qiong Yang,et al.  Association of amine biomarkers with incident dementia and Alzheimer's disease in the Framingham Study , 2017, Alzheimer's & Dementia.

[3]  G. Oxenkrug,et al.  Peripheral Tryptophan - Kynurenine Metabolism Associated with Metabolic Syndrome is Different in Parkinson's and Alzheimer's Diseases. , 2017, Endocrinology, diabetes and metabolism journal.

[4]  Sterling C. Johnson,et al.  Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis , 2017, JAMA neurology.

[5]  M. Garg,et al.  Alterations in erythrocyte fatty acid composition in preclinical Alzheimer’s disease , 2017, Scientific Reports.

[6]  Henrik Zetterberg,et al.  Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease , 2017, JAMA neurology.

[7]  Bruce V. Taylor,et al.  Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression , 2017, Scientific Reports.

[8]  C. Lim,et al.  Kynurenines, Gender and Neuroinflammation; Showcase Schizophrenia , 2016, Neurotoxicity Research.

[9]  C. Jack,et al.  Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria , 2016, Alzheimer's & Dementia.

[10]  B. Brew,et al.  Expression of the Kynurenine Pathway in Human Peripheral Blood Mononuclear Cells: Implications for Inflammatory and Neurodegenerative Disease , 2015, PloS one.

[11]  L. Vécsei,et al.  Alzheimer's disease, astrocytes and kynurenines. , 2015, Current Alzheimer research.

[12]  W. Weckwerth,et al.  Iron chelation and redox chemistry of anthranilic acid and 3-hydroxyanthranilic acid: A comparison of two structurally related kynurenine pathway metabolites to obtain improved insights into their potential role in neurological disease development , 2015, Journal of organometallic chemistry.

[13]  M. Brosnan,et al.  Tryptophan catabolism and vitamin B-6 status are affected by gender and lifestyle factors in healthy young adults. , 2015, The Journal of nutrition.

[14]  C. Rowe,et al.  Comparison of MR-less PiB SUVR quantification methods , 2015, Neurobiology of Aging.

[15]  H. Kiiveri,et al.  A blood-based predictor for neocortical Aβ burden in Alzheimer’s disease: results from the AIBL study , 2014, Molecular Psychiatry.

[16]  M. Lynch.  The impact of neuroimmune changes on development of amyloid pathology; relevance to Alzheimer's disease , 2014, Immunology.

[17]  Olivier Salvado,et al.  MR-Less Surface-Based Amyloid Assessment Based on 11C PiB PET , 2014, PloS one.

[18]  A. Simmons,et al.  Inflammatory Proteins in Plasma Are Associated with Severity of Alzheimer’s Disease , 2013, PloS one.

[19]  H. Hampel,et al.  Increased 3-Hydroxykynurenine serum concentrations differentiate Alzheimer’s disease patients from controls , 2013, European Archives of Psychiatry and Clinical Neuroscience.

[20]  Ronald C. Petersen,et al.  Identification of Altered Metabolic Pathways in Plasma and CSF in Mild Cognitive Impairment and Alzheimer’s Disease Using Metabolomics , 2013, PloS one.

[21]  Gilles J. Guillemin,et al.  Expression of Tryptophan 2,3-Dioxygenase and Production of Kynurenine Pathway Metabolites in Triple Transgenic Mice and Human Alzheimer's Disease Brain , 2013, PloS one.

[22]  Justin Bedo,et al.  Blood-based protein biomarkers for diagnosis of Alzheimer disease. , 2012, Archives of neurology.

[23]  R. Schwarcz,et al.  Kynurenines in the mammalian brain: when physiology meets pathology , 2012, Nature Reviews Neuroscience.

[24]  H. Chertkow,et al.  Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample , 2012, Neurology.

[25]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[26]  George Perry,et al.  Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease , 2010, Redox report : communications in free radical research.

[27]  B. Baban,et al.  Dendritic Cells, Indoleamine 2,3 Dioxygenase and Acquired Immune Privilege , 2010, International reviews of immunology.

[28]  C. Rowe,et al.  The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease , 2009, International Psychogeriatrics.

[29]  L. Ferrucci.  The Baltimore Longitudinal Study of Aging (BLSA): a 50-year-long journey and plans for the future. , 2008, The journals of gerontology. Series A, Biological sciences and medical sciences.

[30]  F. Schmidt.  Meta-Analysis , 2008 .

[31]  H. Akimoto,et al.  Up-regulation of the brain indoleamine 2,3-dioxygenase activity in a mouse model of Alzheimer's disease by systemic endotoxin challenge , 2007 .

[32]  R. Tibshirani,et al.  Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.

[33]  D. Brann,et al.  Neurotrophic and neuroprotective actions of estrogen: Basic mechanisms and clinical implications , 2007, Steroids.

[34]  János Kálmán,et al.  Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease , 2007, Neurochemistry International.

[35]  B. Brew,et al.  Indoleamine 2,3 dioxygenase and quinolinic acid Immunoreactivity in Alzheimer's disease hippocampus , 2005, Neuropathology and applied neurobiology.

[36]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[37]  K. Borowicz,et al.  Neuroprotective role of testosterone in the nervous system. , 2004, Polish journal of pharmacology.

[38]  R. Yolken,et al.  Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia , 2004, Neurobiology of Disease.

[39]  B. Brew,et al.  A&bgr;1-42 induces production of quinolinic acid by human macrophages and microglia , 2003, Neuroreport.

[40]  B. Brew,et al.  Concurrent quantification of quinolinic, picolinic, and nicotinic acids using electron-capture negative-ion gas chromatography-mass spectrometry. , 2002, Analytical biochemistry.

[41]  B. Brew,et al.  Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection , 2001, Journal of neurochemistry.

[42]  M. Namboodiri,et al.  Selective metabolism of kynurenine in the spleen in the absence of indoleamine 2,3-dioxygenase induction. , 2000, Immunology letters.

[43]  A. Placzek,et al.  Alzheimer's β-amyloid peptides induce inflammatory cascade in human vascular cells: the roles of cytokines and CD40 , 1998, Brain Research.

[44]  R. Brookmeyer,et al.  A prospective study of estrogen replacement therapy and the risk of developing Alzheimer''s disease , 1997 .

[45]  Yaakov Stern,et al.  Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease , 1996, The Lancet.

[46]  N. Hagino,et al.  Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. , 1994, Endocrine journal.

[47]  R. Schwarcz,et al.  Blood–Brain Barrier Transport of Kynurenines: Implications for Brain Synthesis and Metabolism , 1991, Journal of neurochemistry.

[48]  E. Werner,et al.  Characteristics of interferon induced tryptophan metabolism in human cells in vitro. , 1989, Biochimica et biophysica acta.

[49]  H. Fillit,et al.  Observations in a preliminary open trial of estradiol therapy for senile dementia-alzheimer's type , 1986, Psychoneuroendocrinology.

[50]  M. Salter,et al.  The role of tryptophan 2,3-dioxygenase in the hormonal control of tryptophan metabolism in isolated rat liver cells. Effects of glucocorticoids and experimental diabetes. , 1985, The Biochemical journal.

[51]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[52]  D. Rose.  Aspects of tryptophan metabolism in health and disease: a review. , 1972, Journal of clinical pathology.

[53]  J. Leklem.  Quantitative aspects of tryptophan metabolism in humans and other species: a review. , 1971, The American journal of clinical nutrition.

[54]  F. McGinty,et al.  Influence of androgens upon tryptophan metabolism in man. , 1969, Life sciences.

[55]  D. Rose.  The influence of sex, age and breast cancer on tryptophan metabolism. , 1967, Clinica chimica acta; international journal of clinical chemistry.

[56]  H. Woodrow,et al.  : A Review of the , 2018 .

[57]  Per Magne Ueland,et al.  Kynurenine Pathway Metabolites in Alzheimer's Disease. , 2017, Journal of Alzheimer's disease : JAD.

[58]  K. Becker,et al.  Redox Report Communications in Free Radical Research , 2017 .

[59]  V L Villemagne,et al.  Associations between gonadotropins, testosterone and β amyloid in men at risk of Alzheimer’s disease , 2014, Molecular Psychiatry.

[60]  D. Fuchs,et al.  Carbonyl proteins as a clinical marker in Alzheimer's disease and its relation to tryptophan degradation and immune activation. , 2010, Clinical laboratory.

[61]  V. Preedy,et al.  Prospective Cohort Study , 2010 .

[62]  George Perry,et al.  Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. , 2010, Journal of Alzheimer's disease : JAD.

[63]  D. Pawlak,et al.  Kynurenine and its metabolites in Alzheimer's disease patients. , 2010, Advances in medical sciences.

[64]  B. Brew,et al.  Expression of indoleamine 2,3‐dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons , 2005, Glia.

[65]  D. Fuchs,et al.  Tryptophan degradation and immune activation in Alzheimer's disease , 2000, Journal of Neural Transmission.

[66]  C. Tamminga.  Gender and schizophrenia. , 1997, The Journal of clinical psychiatry.